Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Stock Quotes and News

Raptor Pharmaceutical Corp. (RPTP) 9.16 -0.03

Price Open:	7.82	Day's Range:	0.00000 - 11.98000
Price Close:	7.83	52wk Range:	0.00000 - 11.98000
Price Day Change:	-0.03	Volume:	462,110
Price % Change:	-0.38	Market Cap:	432.4M
Bid:	5.90000	PE Ratio:	0
Ask:	9.16000	EPS Diluted:	-0.838

Trade RPTP NOW!

The Latest On RPTP

Stocks to Watch for June 19, 2013 6/19/13 9:08am

Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome 5/7/13 7:04am

Raptor Pharmaceutical's PROCYSBI Receives FDA Approval for the Treatment of Nephropathic Cystinosis 5/1/13 4:43pm

13 Drugs Pending FDA Approval in 2013 3/26/13 1:19pm

UPDATE: Wedbush Maintains Raptor Pharmaceutical at Outperform as FDA Pushes Back PDUFA Date 12/31/12 11:48am

Canaccord Genuity Reiterates Buy Rating, $11 PT on Raptor Pharmaceutical 12/26/12 9:51am

Raptor Pharma Offers Update on PROCYSBI NDA Review 12/21/12 5:32pm

Raptor Pharmaceutical Announces Positive Data on RP103 Extension Study 11/5/12 8:32am

Raptor Pharmaceutical Presents PROCYSBI (RP103) Extension Study Data at the ASN Annual Meeting 10/17/12 6:43am

A Peek Into The Market Before The Trading Starts 10/10/12 7:18am

Raptor Pharmaceutical Obtains Tissue Fibrotic Disease Intellectual Property 10/10/12 6:41am

Raptor Pharmaceutical Announces Issuance of Key European Patent Protecting the Cysteamine Portfolio 7/30/12 6:37am

Press Releases

Raptor's PROCYSBI(TM) Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients 6/19/13 GlobeNewswire

Raptor Pharmaceutical to Present at Upcoming Investor Conference 6/12/13 GlobeNewswire

Record Use of At-the-Market (ATM) Offerings Continues in 2013 with $161 Million Raised by U.S. Life Sciences Companies in First Quarter, Reports Brinson Patrick 5/28/13 Newswire

Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results 5/8/13 GlobeNewswire

Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome From French Research Institutes 5/7/13 GlobeNewswire

Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis 5/1/13 Newswire

Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis 4/30/13 Newswire

Raptor Pharmaceutical Corp. Reports Financial Results for the Transition Period From September 1, 2012 to December 31, 2012 3/14/13 GlobeNewswire

Raptor Pharmaceutical Corp. to Present at the Cowen and Company 33rd Annual Health Care Conference 2/26/13 GlobeNewswire

Faruqi & Faruqi, LLP is Investigating Raptor Pharmaceutical Corporation on Behalf of its Shareholders - RPTP 2/12/13 Newswire

Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences 2/5/13 GlobeNewswire

Raptor Pharmaceutical Corp. Reports First Quarter Fiscal Year 2013 Financial Results 1/9/13 GlobeNewswire

Get the latest RPTP stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Raptor Pharmaceutical Corp. stock price.

Partner Headlines

Trading Raptor Pharmaceutical (RPTP) is Going to Take a Little Strategic Thinking 4/2/13

Bearish MACD for Raptor Pharmaceutical Corp. - Tale of the Tape 2/11/13

Raptor Pharmaceutical Corp (RPTP) CEO Christopher M Starr sells 10,088 Shares 1/2/13

Raptor Drug FDA Action Date Delayed - Analyst Blog 12/28/12

Citrix Systems, Teradata Among Stocks Down on Above-average Volume Friday 7/6/12

Raptor Pharmaceutical Corp. (RPTP) CEO Christopher M Starr sells 10,085 Shares 7/2/12

Raptor Pharmaceutical Corp. (RPTP) CFO Kim R Tsuchimoto sells 3,559 Shares 6/18/12

Your Next Best Biotech Bets: RPTP, APRI, OREX 6/13/12

Raptor Pharmaceutical Corp. (RPTP) CFO Kim R Tsuchimoto sells 3,559 Shares 4/17/12

Zacks.com featured expert Kevin Matras highlights: Antares Pharma, Inc., Global Cash Access Holdings, Inc., InnerWorkings, Inc., Raptor Pharmaceuticals Corp. and TASER International, Inc. - Press Releases 11/22/11

Explosive Stocks Under $10 - Screen of the Week 11/22/11